REVENUE (Tables)

3 Months Ended

Sep. 30, 2020

Disaggregation of Revenue [Line Items]

Financing Receivable, Allowance for Credit Loss [Table Text Block]

The rollforward for the allowance for credit losses for the nine months ended September 30, 2020, is as follows:

	For the Nine Months Ended September 30, 2020
	Accounts Receivable		Unbilled Services		Note and Other Receivables		Total
Allowance for credit losses as of December 31, 2019	$	19.0	$	2.3	$	—	$	21.3
Current expected credit losses opening balance impact on retained earnings	1.8		0.2		5.0		7.0
Plus, credit loss expense	10.0		3.9		0.7		14.6
Less, write offs	4.2		0.1		—		4.3
Ending allowance for credit losses	$	26.6	$	6.3	$	5.7	$	38.6

Contract with Customer, Asset and Liability [Table Text Block]

	September 30, 2020		December 31, 2019
Receivables, which are included in accounts receivable	$	834.0	$	771.1
Unbilled services	609.8		483.7
Unearned revenue	492.9		449.2

Disaggregation of Revenue [Table Text Block]

The Company's revenues by segment payers/customer groups for the three and nine months ended September 30, 2020, and 2019, were as follows:

	For the Three Months Ended September 30, 2020
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	21	%	1	%	—	%	—	%	—	%	—	%	22	%
Patients	5	%	—	%	—	%	—	%	—	%	—	%	5	%
Medicare and Medicaid	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Third-party	33	%	1	%	—	%	—	%	—	%	—	%	34	%
Total LCD revenues by payer	66	%	2	%	—	%	—	%	—	%	—	%	68	%
CDD
Biopharmaceutical and medical device companies	16	%	—	%	4	%	4	%	2	%	6	%	32	%
Total revenues	82	%	2	%	4	%	4	%	2	%	6	%	100	%

	For the Three Months Ended September 30, 2019
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Third-party	25	%	2	%	—	%	—	%	—	%	—	%	27	%
Total LCD revenues by payer	57	%	3	%	—	%	—	%	—	%	—	%	60	%
CDD
Biopharmaceutical and medical device companies	21	%	—	%	5	%	4	%	3	%	7	%	40	%
Total revenues	78	%	3	%	5	%	4	%	3	%	7	%	100	%

	For the Nine Months Ended September 30, 2020
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	19	%	1	%	—	%	—	%	—	%	—	%	20	%
Patients	6	%	—	%	—	%	—	%	—	%	—	%	6	%
Medicare and Medicaid	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Third-party	29	%	1	%	—	%	—	%	—	%	—	%	30	%
Total LCD revenues by payer	61	%	2	%	—	%	—	%	—	%	—	%	63	%
CDD
Biopharmaceutical and medical device companies	18	%	—	%	5	%	4	%	3	%	7	%	37	%
Total revenues	79	%	2	%	5	%	4	%	3	%	7	%	100	%

	For the Nine Months Ended September 30, 2019
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%
Total LCD revenues by payer	58	%	3	%	—	%	—	%	—	%	—	%	61	%
CDD
Biopharmaceutical and medical device companies	20	%	—	%	4	%	5	%	3	%	7	%	39	%
Total revenues	78	%	3	%	4	%	5	%	3	%	7	%	100	%

Capitalized Contract Cost [Table Text Block]

	September 30, 2020		December 31, 2019
Sales commission assets	$	32.8	$	28.6
Deferred contract fulfillment costs	12.9		14.9
Total	$	45.7	$	43.5